No evidence for a putative involvement of platelet‐activating factor in systemic lupus erythematosus without active nephritis

Denizot, Yves; Liozon, É.; Guglielmi, Laurence; Ly, Kim-Heang; Soria, P.; Loustaud, V.; Vidal, É.; Jauberteau, Marie‐Odile

doi:10.1080/0962935031000097718

Cited by 2 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Identification of PAF was based on the stringent functional and biophysical criteria detailed above. It is unlikely that circulating blood accounted for the amount of PAF found in the thyroid since: (i) tissue samples were extensively rinsed before being frozen; (ii) the mean amount of bioactive PAF found in blood was 10 pg/ml (27,28), as compared with the 3 pg/mg found in thyroid tissue; (iii) similar amounts of PAF were found in tissue samples from lung and colon (21,23); and (iv) stimulated FRTL5 cells (a normal rat thyroid cell line) produced PAF in the presence of the lyso-PAF precursor (29). The presence of the lyso-PAF precursor is consistent with the presence of a PLA 2 activity in the thyroid gland; PLA 2 mRNA Figure 3 Investigation of AHA (A) and PLA 2 activity (B) in diseased ('ill') thyroid tissues.…”

Section: Discussionmentioning

confidence: 99%

Platelet-activating factor and human thyroid cancer

Denizot¹,

Chianea²,

Labrousse³

et al. 2005

eur j endocrinol

Self Cite

View full text Add to dashboard Cite

Objective: Platelet-activating factor (PAF) is a pro-inflammatory and angiogenic lipid mediator involved in several types of cancer in humans. The levels of PAF, lyso-PAF (the PAF precursor), phospholipase A 2 activity (PLA 2 , the enzymatic activity implicated in lyso-PAF formation) and acetylhydrolase activity (AHA, the PAF-degrading enzyme) were investigated in various diseased thyroid tissues. Subjects: Control and diseased tissue of patients with a hyperplastic goitre (n ¼ 14), a benign adenoma (n ¼ 12) and a papillary thyroid carcinoma (n ¼ 15) were investigated. Results: PAF receptor transcripts were found in the human thyroid tissue. PAF, lyso-PAF, PLA 2 and AHA were present in control thyroid tissues, their levels being significantly correlated with each other, suggesting tiny regulations of the PAF metabolic pathways inside the thyroid gland. PAF, lyso-PAF, PLA 2 and AHA levels remained unchanged in diseased tissues of patients with a hyperplastic goitre, a benign adenoma and a papillary thyroid carcinoma. No difference was found between PAF, lyso-PAF, PLA 2 and AHA levels with respect to the TNM tumour status and the histological subtype of papillary thyroid carcinoma. No correlation was found between tissue PAF levels and those of vascular endothelial growth factor and basic fibroblast growth factor, two angiogenic growth factors involved in thyroid cancer and that mediate their effect through PAF release in breast and colorectal cancer. Conclusion: PAF, PAF receptor transcripts and the enzymatic activities implicated in PAF production and degradation are present in the thyroid gland. While the physiological role of PAF is presently unknown in thyroid physiology, this study highlights no evidence for a potentially important role of PAF during human thyroid cancer, a result that markedly differs from breast and colorectal ones.European Journal of Endocrinology 153 31-40

show abstract

Section: Discussionmentioning

confidence: 99%

Platelet-activating factor and human thyroid cancer

Denizot¹,

Chianea²,

Labrousse³

et al. 2005

eur j endocrinol

Self Cite

View full text Add to dashboard Cite

show abstract

Serum lipoprotein‐associated phospholipase A2 activity in Chinese patients with systemic lupus erythematosus

Feng,

Wang,

Gao

2024

iLABMED

View full text Add to dashboard Cite

BackgroundFew studies have explored the association between lipoprotein‐associated phospholipase A2 (Lp‐PLA2) and systemic lupus erythematosus (SLE). However, most of these studies have investigated only European patient populations and have come to contradictory conclusions. Furthermore, few studies have been conducted on Chinese patient groups. This study aimed to explore the association between serum Lp‐PLA2 activity and SLE in a Chinese patient group.MethodsSerum Lp‐PLA2 activity was detected in 154 SLE patients and 55 age‐, sex‐, and body mass index‐matched healthy controls. Information concerning the anthropometric data, clinical manifestations, SLE Disease Activity Index 2000 (SLEDAI‐2K), complement C3 (C3), and complement C4 (C4) erythrocyte sedimentation rate (ESR), and autoantibodies were evaluated.ResultsThe average level of serum Lp‐PLA2 activity was 221 ± 56 U/L in SLE patients compared with 160 ± 37 U/L in healthy controls (p < 0.001). SLE patients that presented with nephritis, anemia, and fibrinolytic abnormality had higher serum Lp‐PLA2 activity than SLE patients who did not present with these symptoms (p < 0.05), and the levels of serum Lp‐PLA2 activity correlated with the severity of the clinical manifestations (p < 0.001). There was no correlation between serum Lp‐PLA2 activity and serum autoantibodies levels (p > 0.05). According to Spearman’s rank correlation coefficient, ESR, SLEDAI‐2K, C3, and C4 significantly correlated with serum Lp‐PLA2 activity (p < 0.001). According to binary logistic regression, Lp‐PLA2 activity was independently associated with active SLE in patients (OR 1.049; 95% CI: 1.025–1.073, p < 0.001).ConclusionsSerum Lp‐PLA2 activity is associated with some clinical manifestations (nephritis, anemia, and fibrinolytic abnormality) in SLE patients, and its activity may contribute to the development of SLE disease. These findings provide new insight into the pathogenesis of SLE.

show abstract

No evidence for a putative involvement of platelet‐activating factor in systemic lupus erythematosus without active nephritis

Cited by 2 publications

References 25 publications

Platelet-activating factor and human thyroid cancer

Platelet-activating factor and human thyroid cancer

Serum lipoprotein‐associated phospholipase A2 activity in Chinese patients with systemic lupus erythematosus

Contact Info

Product

Resources

About